Johnson & Johnson will subscribe for new shares in Alligator Bioscience as part of a licensing agreement for its immuno-oncology drug candidate.
Janssen Biotech, a subsidiary of healthcare conglomerate Johnson & Johnson, has signed an exclusive worldwide licensing agreement with Sweden-based Alligator Bioscience for one of its antibody-based drugs.
The license gives Janssen Biotech the rights to develop and commercialise ADC-1013, an immune system-based treatment for cancer that is currently in phase 1 clinical trials. For these rights, Alligator Bioscience has received an undisclosed upfront payment along with contracted future milestone payments.
Alligator Bioscience will continue its phase 1 trials with Janssen…
